Jim Silverman is the managing member of RRC Bio Fund LP, a Boston-based hedge fund focused on small-cap biotech. RRC Bio was launched in 2007. Silverman also founded Risk/Reward Capital Management in 1997, a registered investment advisory. He lives in Cambridge, Mass., and received a BBA in finance from The George Washington University.
Iclusig may find use in other cancers and '113 is better than the market believes.
Through four reverse stock splits, Cell Therapeutics has lost 99% of its value.
Instead of selling stock whenever the wind blows, biotech execs should be buying.
With President Obama re-elected it's back to discussing changes to the tax code and the effect on dividends.
The strange but true tale of a beleaguered, bankrupt biotech firm with 100 quadrillion shares outstanding.
How best to invest in the next important clinical trial catalyst facing Celgene.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.